| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Integrative Physiology and Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, Texas 76107–2699
Pyruvate, a metabolic product of glycolysis and an oxidizable fuel in myocardium, increases cardiac mechanical performance and energy reserves, especially when supplied at supraphysiological concentrations. The inotropic effects of pyruvate are most impressive in hearts that have been reversibly injured (stunned) by ischemia/reperfusion stress. Glucose appears to be an essential co-substrate for pyruvate's salutary effects in stunned hearts, but other fuels including lactate, acetate, fatty acids, and ketone bodies produce little or no improvement in postischemic function over glucose alone. In contrast to pharmacological inotropism by catecholamines, metabolic inotropism by pyruvate increases cardiac energy reserves and bolsters the endogenous glutathione antioxidant system. Pyruvate enhancement of cardiac function may result from one or more of the following mechanisms: increased cytosolic ATP phosphorylation potential and Gibbs free energy of ATP hydrolysis, enhanced sarcoplasmic reticular calcium ion uptake and release, decreased cytosolic inorganic phosphate concentration, oxyradical scavenging via direct neutralization of peroxides and/or enhancement of the intracellular glutathione/NADPH antioxidant system, and/or closure of mitochondrial permeability transition pores. This review aims to summarize evidence for each of these mechanisms and to consider the potential utility of pyruvate as a therapeutic intervention for clinical management of cardiac insufficiency.
This article has been cited by other articles:
|
|
 |
|
  X. Li, K. Tang, B. Xie, S. Li, and G. J. Rozanski Regulation of Kv4 channel expression in failing rat heart by the thioredoxin system Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H416 - H424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Oliveira, S. Guatimosim, C. H. Castro, D. T. Galan, S. Lauton-Santos, A. M. Ribeiro, A. P. Almeida, and J. S. Cruz Abolition of reperfusion-induced arrhythmias in hearts from thiamine-deficient rats Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H394 - H401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Su, Z. Wang, Y. Cai, M. Remmelink, and J.-L. Vincent Beneficial Effects of Ethyl Pyruvate in Septic Shock From Peritonitis Arch Surg, February 1, 2007; 142(2): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Knott, J. Sun, Y. Lei, M.-G. Ryou, A. H. Olivencia-Yurvati, and R. T. Mallet Pyruvate Mitigates Oxidative Stress During Reperfusion of Cardioplegia-Arrested Myocardium. Ann. Thorac. Surg., March 1, 2006; 81(3): 928 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Okere, T. A. McElfresh, D. Z. Brunengraber, W. Martini, J. P. Sterk, H. Huang, M. P. Chandler, H. Brunengraber, and W. C. Stanley Differential effects of heptanoate and hexanoate on myocardial citric acid cycle intermediates following ischemia-reperfusion J Appl Physiol, January 1, 2006; 100(1): 76 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Mallet, J. Sun, E. M. Knott, A. B. Sharma, and A. H. Olivencia-Yurvati Metabolic Cardioprotection by Pyruvate: Recent Progress Experimental Biology and Medicine, July 1, 2005; 230(7): 435 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhou, J. E. Salem, G. M. Saidel, W. C. Stanley, and M. E. Cabrera Mechanistic model of cardiac energy metabolism predicts localization of glycolysis to cytosolic subdomain during ischemia Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2400 - H2411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tursun, M. Tashiro, and M. Konishi Modulation of Mg2+ Efflux from Rat Ventricular Myocytes Studied with the Fluorescent Indicator Furaptra Biophys. J., March 1, 2005; 88(3): 1911 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Woo, M. D. Taylor, J. E. Cohen, V. Jayasankar, L. T. Bish, J. Burdick, T. J. Pirolli, M. F. Berry, V. Hsu, and T. Grand Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1262 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Khairallah, F. Labarthe, B. Bouchard, G. Danialou, B. J. Petrof, and C. Des Rosiers Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1461 - H1470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P Halestrap, S. J Clarke, and S. A Javadov Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection Cardiovasc Res, February 15, 2004; 61(3): 372 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Doenst, C. Schlensak, and F. Beyersdorf Cardioplegia in pediatric cardiac surgery: do we believe in magic? Ann. Thorac. Surg., May 1, 2003; 75(5): 1668 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Rozanski and Z. Xu Glutathione and K+ channel remodeling in postinfarction rat heart Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2346 - H2355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nemoto, K. Takeda, Z.-X. Yu, V. J. Ferrans, and T. Finkel Role for Mitochondrial Oxidants as Regulators of Cellular Metabolism Mol. Cell. Biol., October 1, 2000; 20(19): 7311 - 7318. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Rozanski and Z. Xu Glutathione and K+ channel remodeling in postinfarction rat heart Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2346 - H2355. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
